Context Therapeutics Inc. (NASDAQ:CNTX – Free Report) – Equities researchers at HC Wainwright boosted their Q3 2026 earnings estimates for shares of Context Therapeutics in a report issued on Thursday, August 6th. HC Wainwright analyst E. Bodnar now forecasts that the company will earn ($0.07) per share for the quarter, up from their prior forecast of ($0.11). The consensus estimate for Context Therapeutics’ current full-year earnings is ($0.40) per share. HC Wainwright also issued estimates for Context Therapeutics’ Q4 2026 earnings at ($0.08) EPS, FY2026 earnings at ($0.40) EPS, FY2027 earnings at ($0.43) EPS, FY2028 earnings at ($0.42) EPS, FY2029 earnings at ($0.23) EPS and FY2030 earnings at $0.00 EPS.
Other research analysts have also recently issued reports about the company. Maxim Group lowered their target price on Context Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a research note on Tuesday, June 16th. Citigroup reaffirmed an “outperform” rating on shares of Context Therapeutics in a research report on Thursday, August 6th. Lifesci Capital cut Context Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Thursday, August 6th. Weiss Ratings downgraded Context Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 6th. Finally, Wall Street Zen lowered shares of Context Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Monday, July 20th. Eight analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $6.17.
Context Therapeutics Trading Up 3.0%
Shares of NASDAQ CNTX opened at $0.47 on Monday. The stock has a market cap of $42.80 million, a P/E ratio of -0.97 and a beta of 1.74. Context Therapeutics has a 12-month low of $0.43 and a 12-month high of $3.62. The business’s fifty day simple moving average is $0.78 and its 200-day simple moving average is $1.90.
Context Therapeutics (NASDAQ:CNTX – Get Free Report) last posted its quarterly earnings results on Wednesday, August 5th. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.06).
Hedge Funds Weigh In On Context Therapeutics
Several large investors have recently bought and sold shares of CNTX. Octagon Capital Advisors LP purchased a new stake in Context Therapeutics during the 1st quarter worth about $13,755,000. Blue Owl Capital Holdings LP increased its holdings in shares of Context Therapeutics by 0.3% in the 4th quarter. Blue Owl Capital Holdings LP now owns 7,432,906 shares of the company’s stock valued at $10,926,000 after acquiring an additional 25,000 shares during the last quarter. BlackRock Inc. purchased a new position in shares of Context Therapeutics in the 2nd quarter valued at about $3,417,000. Deutsche Bank AG acquired a new stake in shares of Context Therapeutics during the 2nd quarter worth about $50,000. Finally, Bank of New York Mellon Corp acquired a new stake in shares of Context Therapeutics during the 2nd quarter worth about $61,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.
About Context Therapeutics
Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.
With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.
Featured Articles
- Five stocks we like better than Context Therapeutics
- Atlassian Just Pulled Off the Software Comeback Wall Street Wanted
- AST SpaceMobile Earnings Just Reminded Investors How Risky Space Can Be
- NVIDIA’s Rally Sets Up a Bigger Test Ahead of Earnings
- Apple’s Next iPhone Could Test How Much Pricing Power Is Left
Receive News & Ratings for Context Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Context Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
